DI
Divi's Laboratories
DIVISLAB.NS·NSEHyderabad INFounded 199016,000 employees
Large CappharmaPublicOncology
Platform: API CDMO
Market Cap
$18B
All Drugs
6
Clinical Trials
16
Failed / Terminated
6
FDA Approved
0
Stock Price & Catalysts (DIVISLAB.NS)
Loading DIVISLAB.NS stock data...
Drug Pipeline (6 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| DIV-3233 | DIV-3233 | Phase 2/3 | 2 | PD-L1 | Cervical CaMM | ||
| DIV-7153 | DIV-7153 | Preclinical | 2 | TIM-3 | PompeIPF | ||
| Cevirelsin | DIV-2530 | Phase 2 | 2 | TYK2 | AMLBladder Ca | ||
| DIV-9629 | DIV-9629 | Phase 3 | 4 | HER2 | Urothelial Ca | ||
| Suracagene | DIV-8003 | Phase 3 | 4 | BCMA | Atopic DermEndometrial Ca | ||
| DIV-5162 | DIV-5162 | Preclinical | 2 | USP1 | MyelofibrosisMS |
SEC Filings & Financial Documents
SEC filings are not available for NSE-listed companies.
Divi's Laboratories trades on NSE (IN). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (16)